The European Medicines Agency (EMA) recommends extension of indications for daratumumabAccess, Myeloma21 October 2019
European Commission approves elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory myelomaAccess, Myeloma28 August 2019
Janssen seeks European marketing authorisation for subcutaneous (under the skin) daratumumab (Darzalex®)Access, Myeloma19 July 2019
HARMONY reaches milestone capturing data from 45,000 patients with blood cancersMPE, Myeloma25 June 2019
Takeda announces discontinuation of the phase 3 clinical trial TOURMALINE-AL1 in AL amyloidosisAccess, AL amyloidosis6 June 2019
